210 related articles for article (PubMed ID: 35157519)
1. Prothymosin Alpha: A Novel Contributor to Estradiol Receptor Alpha-Mediated CD8
Passos LSA; Jha PK; Becker-Greene D; Blaser MC; Romero D; Lupieri A; Sukhova GK; Libby P; Singh SA; Dutra WO; Aikawa M; Levine RA; Nunes MCP; Aikawa E
Circulation; 2022 Feb; 145(7):531-548. PubMed ID: 35157519
[TBL] [Abstract][Full Text] [Related]
2. Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.
Ioannou K; Derhovanessian E; Tsakiri E; Samara P; Kalbacher H; Voelter W; Trougakos IP; Pawelec G; Tsitsilonis OE
BMC Immunol; 2013 Sep; 14():43. PubMed ID: 24053720
[TBL] [Abstract][Full Text] [Related]
3. Prothymosin α variants isolated from CD8+ T cells and cervicovaginal fluid suppress HIV-1 replication through type I interferon induction.
Teixeira A; Yen B; Gusella GL; Thomas AG; Mullen MP; Aberg J; Chen X; Hoshida Y; van Bakel H; Schadt E; Basler CF; García-Sastre A; Mosoian A
J Infect Dis; 2015 May; 211(9):1467-75. PubMed ID: 25404520
[TBL] [Abstract][Full Text] [Related]
4. The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients.
Skopeliti M; Voutsas IF; Klimentzou P; Tsiatas ML; Beck A; Bamias A; Moraki M; Livaniou E; Neagu M; Voelter W; Tsitsilonis OE
Cancer Immunol Immunother; 2006 Oct; 55(10):1247-57. PubMed ID: 16453152
[TBL] [Abstract][Full Text] [Related]
5. Synergy between interleukin-2 and prothymosin alpha for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas.
Voutsas IF; Baxevanis CN; Gritzapis AD; Missitzis I; Stathopoulos GP; Archodakis G; Banis C; Voelter W; Papamichail M
Cancer Immunol Immunother; 2000 Oct; 49(8):449-58. PubMed ID: 11043852
[TBL] [Abstract][Full Text] [Related]
6. Prothymosin-α Variants Elicit Anti-HIV-1 Response via TLR4 Dependent and Independent Pathways.
Gusella GL; Teixeira A; Aberg J; Uversky VN; Mosoian A
PLoS One; 2016; 11(6):e0156486. PubMed ID: 27310139
[TBL] [Abstract][Full Text] [Related]
7. Prothymosin α activates type I collagen to develop a fibrotic placenta in gestational diabetes.
Wu HT; Kang L; Su YC; Ou HY; Chan FY; Chen YC; Su BH; Wang YS; Wu CL; Shiau AL; Wu P
Clin Sci (Lond); 2020 Sep; 134(18):2435-2445. PubMed ID: 32909608
[TBL] [Abstract][Full Text] [Related]
8. Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction.
Mosoian A; Teixeira A; Burns CS; Sander LE; Gusella GL; He C; Blander JM; Klotman P; Klotman ME
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10178-83. PubMed ID: 20479248
[TBL] [Abstract][Full Text] [Related]
9. The Role of Interleukin-13 in Patients with Rheumatic Valvular Fibrosis: A Clinical and Histological Study.
Liu Q; Qiao WH; Li FF; Deng P; Hu ZW
J Heart Valve Dis; 2015 Jul; 24(4):496-501. PubMed ID: 26897823
[TBL] [Abstract][Full Text] [Related]
10. Identification of receptors for prothymosin alpha on human lymphocytes.
Piñeiro A; Begoña Bugia M; Pilar Arias M; Cordero OJ; Nogueira M
Biol Chem; 2001 Oct; 382(10):1473-82. PubMed ID: 11727831
[TBL] [Abstract][Full Text] [Related]
11. Prothymosin Alpha: An Alarmin and More..
Samara P; Karachaliou CE; Ioannou K; Papaioannou NE; Voutsas IF; Zikos C; Pirmettis I; Papadopoulos M; Kalbacher H; Livaniou E; Tsitsilonis OE; Voelter W
Curr Med Chem; 2017; 24(17):1747-1760. PubMed ID: 28521686
[TBL] [Abstract][Full Text] [Related]
12. Evidence for ProTα-TLR4/MD-2 binding: molecular dynamics and gravimetric assay studies.
Omotuyi O; Matsunaga H; Ueda H
Expert Opin Biol Ther; 2015; 15 Suppl 1():S223-9. PubMed ID: 25604147
[TBL] [Abstract][Full Text] [Related]
13. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice.
Voutsas IF; Pistamaltzian N; Tsiatas ML; Skopeliti M; Katsila T; Mavrothalassiti I; Spyrou S; Dimopoulos MA; Tsitsilonis OE; Bamias A
Eur J Cancer; 2013 May; 49(7):1706-14. PubMed ID: 23276721
[TBL] [Abstract][Full Text] [Related]
14. Prothymosin-α interacts with mutant huntingtin and suppresses its cytotoxicity in cell culture.
Dong G; Callegari EA; Gloeckner CJ; Ueffing M; Wang H
J Biol Chem; 2012 Jan; 287(2):1279-89. PubMed ID: 22110140
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation dysregulations in rheumatic heart valve disease.
Shen K; Liu H; Jing R; Yi J; Zhou X
BMC Cardiovasc Disord; 2017 Jun; 17(1):159. PubMed ID: 28623907
[TBL] [Abstract][Full Text] [Related]
16. Proteomic exploitation on prothymosin alpha-induced mononuclear cell activation.
Skopeliti M; Kratzer U; Altenberend F; Panayotou G; Kalbacher H; Stevanovic S; Voelter W; Tsitsilonis OE
Proteomics; 2007 Jun; 7(11):1814-24. PubMed ID: 17474146
[TBL] [Abstract][Full Text] [Related]
17. Development of an ELISA for the quantification of the C-terminal decapeptide prothymosin α(100-109) in sera of mice infected with bacteria.
Samara P; Kalbacher H; Ioannou K; Radu DL; Livaniou E; Promponas VJ; Voelter W; Tsitsilonis O
J Immunol Methods; 2013 Sep; 395(1-2):54-62. PubMed ID: 23831611
[TBL] [Abstract][Full Text] [Related]
18. Rheumatic Heart Valve Disease Pathophysiology and Underlying Mechanisms.
Passos LSA; Nunes MCP; Aikawa E
Front Cardiovasc Med; 2020; 7():612716. PubMed ID: 33537348
[TBL] [Abstract][Full Text] [Related]
19. Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alpha.
Baxevanis CN; Spanakos G; Voutsas IF; Gritzapis AD; Tsitsilonis OE; Mamalaki A; Papamichail M
Cancer Immunol Immunother; 1999; 48(2-3):71-84. PubMed ID: 10414460
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters.
Wang M; Pan JY; Song GR; Chen HB; An LJ; Qu SX
Eur J Surg Oncol; 2007 Mar; 33(2):195-201. PubMed ID: 17046193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
